title: E2F transcription factors and digestive system malignancies: how much do we know?
abstract: The E2F proteins comprise a family of 8 members that function as transcription factors. They are key targets of the retinoblastoma protein (RB) and were initially divided into groups of activators and repressors. Accumulating data suggest that there is no specific role for each individual E2F member. Instead, each E2F can exert a variety of cellular effects, some of which represent opposing ones. For instance, specific E2Fs can activate transcription and repression, promote or hamper cell proliferation, augment or inhibit apoptosis, all being dependent on the cellular context. This complexity reflects the importance that these transcription factors have on a cell's fate. Thus, delineating the specific role for each E2F member in specific malignancies, although not easy, is a challenging and continuously pursued task, especially in view of potential E2F targeted therapies. Therefore, several reviews are continuously trying to evaluate available data on E2F status in various malignancies. Such reviews have attempted to reach a consensus, often in the simplistic form of oncogenes or tumor suppressor genes for the E2Fs. However they frequently miss spatial and temporal alterations of these factors during tumor development, which should also be considered in conjunction with the status of the regulatory networks that these factors participate in. In the current ''Letter to the Editor'', we comment on the flaws, misinterpretations and omissions in one such review article published recently in the World Journal of Gastroenterology regarding the role of E2Fs in digestive system malignancies.
authors.affiliation: Konstantinos Evangelou, Sophia Havaki, Athanassios Kotsinas, Laboratory Histology-Embryology, Medical School, National and Kapodistrian University of Athens, 11527 Goudi, Athens, Greece.
authors.forename: Konstantinos
authors.initials: K
authors.lastname: Evangelou
authors.affiliation: Konstantinos Evangelou, Sophia Havaki, Athanassios Kotsinas, Laboratory Histology-Embryology, Medical School, National and Kapodistrian University of Athens, 11527 Goudi, Athens, Greece.
authors.forename: Sophia
authors.initials: S
authors.lastname: Havaki
authors.affiliation: Konstantinos Evangelou, Sophia Havaki, Athanassios Kotsinas, Laboratory Histology-Embryology, Medical School, National and Kapodistrian University of Athens, 11527 Goudi, Athens, Greece.
authors.forename: Athanassios
authors.initials: A
authors.lastname: Kotsinas
mesh_terms: D000818:Animals; D063646:Carcinogenesis / Q000378:metabolism*; D004067:Digestive System Neoplasms / Q000378:metabolism*; D050684:E2F Transcription Factors / Q000378:metabolism*; D006801:Humans
chemical_list: D050684:E2F Transcription Factors
keywords: Apoptosis; Cancer; Digestive system; E2F; Gastrointestinal tract; Hepatocellular carcinoma; Pancreatic ductal adenocarcinoma; Proliferation; p53; p73
references.citation: Cancer Res. 2012 Feb 1;72(3):571-5
references.pmid: 22298593
references.citation: Carcinogenesis. 2004 Mar;25(3):333-41
references.pmid: 14604889
references.citation: Mol Cell Biol. 1997 Sep;17(9):5508-20
references.pmid: 9271426
references.citation: Oncogene. 2001 Oct 25;20(48):7104-9
references.pmid: 11704835
references.citation: Mol Cell Biol. 2000 May;20(10):3626-32
references.pmid: 10779352
references.citation: Eur J Cancer. 2005 Nov;41(16):2403-14
references.pmid: 16213134
references.citation: Oncogene. 2002 Feb 21;21(9):1359-69
references.pmid: 11857079
references.citation: Tumour Biol. 2002 Mar-Apr;23(2):76-86
references.pmid: 12065845
references.citation: Gastroenterology. 2008 Oct;135(4):1322-32
references.pmid: 18722373
references.citation: Oncogene. 2007 Apr 2;26(15):2166-76
references.pmid: 17401425
references.citation: Mol Cell Biol. 1997 Dec;17(12):7268-82
references.pmid: 9372959
references.citation: Hepatology. 2002 Jun;35(6):1341-50
references.pmid: 12029619
references.citation: Cancer Res. 2001 Oct 1;61(19):7052-5
references.pmid: 11585734
references.citation: Biochem Biophys Res Commun. 2004 May 7;317(3):749-60
references.pmid: 15081404
references.citation: Mol Cell Biol. 2000 May;20(10):3633-9
references.pmid: 10779353
references.citation: Am J Pathol. 2009 Jul;175(1):376-91
references.pmid: 19541929
references.citation: Curr Mol Med. 2006 Nov;6(7):739-48
references.pmid: 17100600
references.citation: Cancer Res. 2007 May 1;67(9):4005-9
references.pmid: 17483310
references.citation: Ann Surg Oncol. 2013 Nov;20(12):4041-54
references.pmid: 22911364
references.citation: Proc Natl Acad Sci U S A. 2010 Jan 5;107(1):246-51
references.pmid: 20018721
references.citation: World J Gastroenterol. 2013 Jun 7;19(21):3189-98
references.pmid: 23745020
references.citation: J Natl Cancer Inst. 2002 Jan 16;94(2):129-42
references.pmid: 11792751
references.citation: Mol Cancer Res. 2004 Apr;2(4):203-14
references.pmid: 15140942
references.citation: Br J Cancer. 1999 Jan;79(1):164-7
references.pmid: 10408709
references.citation: J Biol Chem. 2002 Jun 28;277(26):23493-9
references.pmid: 11980909
references.citation: Cancer Res. 1997 May 1;57(9):1731-4
references.pmid: 9135016
references.citation: Nat Rev Cancer. 2009 Nov;9(11):785-97
references.pmid: 19851314
references.citation: Int J Oncol. 2004 Dec;25(6):1839-47
references.pmid: 15547725
references.citation: FEBS Lett. 2008 Aug 6;582(18):2793-8
references.pmid: 18625225
references.citation: Virchows Arch. 2012 May;460(5):439-46
references.pmid: 22450712
references.citation: World J Gastroenterol. 2011 Jan 28;17(4):470-7
references.pmid: 21274376
references.citation: Cancer Res. 1997 Aug 1;57(15):3126-30
references.pmid: 9242437
references.citation: Oncogene. 2000 Oct 19;19(44):5054-62
references.pmid: 11042693
references.citation: Pathol Res Pract. 2003;199(1):23-8
references.pmid: 12650514
references.citation: Surgery. 2004 Jun;135(6):604-12
references.pmid: 15179366